- Type / Class
- Equity / Common Stock
- Shares outstanding
- 82,201,196
- Total 13F shares
- 68,912,118
- Share change
- -5,205,068
- Total reported value
- $648,484,078
- Put/Call ratio
- 464%
- Price per share
- $9.41
- Number of holders
- 139
- Value change
- -$21,934,653
- Number of buys
- 71
- Number of sells
- 66
Quarterly Holders Quick Answers
What is CUSIP 30233G209?
CUSIP 30233G209 identifies EYPT - EyePoint, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 30233G209:
Top shareholders of EYPT - EyePoint, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| EW Healthcare Partners, L.P. |
3/4/5
|
Other*, 10%+ Owner |
—
class O/S missing
|
3,490,921
|
$87,327,483 | — | 01 Sep 2023 | |
| Cormorant Asset Management, LP |
13F
|
Company |
10%
|
8,325,000
|
$45,121,500 | — | 31 Mar 2025 | |
| FEDERATED HERMES, INC. |
13D/G
13F
|
Company |
6.7%
|
4,599,450
|
$43,281,744 | $0 | 30 Jun 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
8.3%
|
6,804,091
|
$36,878,173 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
7.5%
|
6,200,000
|
$33,604,000 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
7%
|
5,722,045
|
$31,013,483 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13D/G
13F
|
Company |
6.1%
|
4,137,567
|
$27,059,688 | +$820,894 | 31 Dec 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
|
Company |
4.7%
|
3,181,818
|
$20,809,090 | $0 | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.7%
|
3,834,368
|
$20,782,275 | — | 31 Mar 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
4.3%
|
3,572,335
|
$19,362,056 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.8%
|
2,286,089
|
$12,390,602 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
1,593,030
|
$8,635,987 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.9%
|
1,593,211
|
$8,635,204 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.9%
|
1,537,274
|
$8,332,025 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.9%
|
1,531,556
|
$8,301,033 | — | 31 Mar 2025 | |
| Patient Square Capital LP |
13F
|
Company |
1.8%
|
1,481,977
|
$8,032,315 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.6%
|
1,354,014
|
$7,339,000 | — | 31 Mar 2025 | |
| Essex Woodlands Management, Inc. |
13F
|
Company |
1.4%
|
1,169,857
|
$6,340,625 | — | 31 Mar 2025 | |
| Finepoint Capital LP |
13F
|
Company |
1.3%
|
1,081,954
|
$5,864,191 | — | 31 Mar 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
1.3%
|
1,050,000
|
$5,691,000 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.1%
|
864,111
|
$4,683,481 | — | 31 Mar 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.97%
|
797,594
|
$4,322,959 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.91%
|
750,212
|
$4,066,151 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.77%
|
629,879
|
$3,413,945 | — | 31 Mar 2025 | |
| HSBC HOLDINGS PLC |
13F
|
Company |
0.76%
|
625,140
|
$3,386,830 | — | 31 Mar 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.72%
|
593,091
|
$3,214,553 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.61%
|
500,335
|
$2,711,816 | — | 31 Mar 2025 | |
| Therapeutics Ocumension |
3/4/5
|
Director |
—
class O/S missing
|
100,221
|
$2,507,088 | — | 11 Jan 2024 | |
| Ye Liu |
3/4/5
|
Director |
—
class O/S missing
|
100,221
|
$2,507,088 | — | 11 Jan 2024 | |
| Principia Wealth Advisory, LLC |
13F
|
Company |
0.65%
|
533,778
|
$2,439,365 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.54%
|
442,992
|
$2,401,017 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.48%
|
395,345
|
$2,142,769 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.47%
|
387,079
|
$2,097,968 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.43%
|
357,442
|
$1,937,336 | — | 31 Mar 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.43%
|
351,348
|
$1,904,306 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.39%
|
323,860
|
$1,755,321 | — | 31 Mar 2025 | |
| Artia Global Partners LP |
13F
|
Company |
0.39%
|
316,700
|
$1,716,514 | — | 31 Mar 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.31%
|
257,985
|
$1,504,053 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.33%
|
271,611
|
$1,472,132 | — | 31 Mar 2025 | |
| David Scott Jones |
3/4/5
|
SVP & Chief Commercial Officer |
—
mixed-class rows
|
54,291
mixed-class rows
|
$1,437,581 | — | 09 Feb 2024 | |
| AXA S.A. |
13F
|
Company |
0.32%
|
262,809
|
$1,424,425 | — | 31 Mar 2025 | |
| Dario A. Paggiarino |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
68,106
mixed-class rows
|
$1,386,544 | — | 30 Mar 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.28%
|
233,231
|
$1,264,112 | — | 31 Mar 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.28%
|
230,745
|
$1,250,638 | — | 31 Mar 2025 | |
| Laurion Capital Management LP |
13F
|
Company |
0.26%
|
210,006
|
$1,138,233 | — | 31 Mar 2025 | |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC |
13F
|
Company |
0.25%
|
206,605
|
$1,119,799 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.25%
|
202,954
|
$1,100,009 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.24%
|
194,897
|
$1,056,342 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.23%
|
191,144
|
$1,036,000 | — | 31 Mar 2025 | |
| MYDA Advisors LLC |
13F
|
Company |
0.22%
|
180,000
|
$975,600 | — | 31 Mar 2025 |
Institutional Holders of EyePoint, Inc. - Common Stock (EYPT) as of Q2 2025
As of 30 Jun 2025,
EyePoint, Inc. - Common Stock (EYPT) was held by
139 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
68,912,118 shares.
The largest 10 holders included
Cormorant Asset Management, LP, SUVRETTA CAPITAL MANAGEMENT, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., BlackRock, Inc., FEDERATED HERMES, INC., FRANKLIN RESOURCES INC, VANGUARD GROUP INC, TCG Crossover Management, LLC, CITADEL ADVISORS LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
139
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
149
Q2 2025 holders
139
Holder diff
-10
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.